Ventracor chalks up first revenues

By Ruth Beran
Tuesday, 20 September, 2005

Ventracor (ASX:VCR) has received its first revenues, in the form of a cheque from the University of Maryland Medical Centre as payment for a VentrAssist left ventricular assist device (LVAD) recently implanted in a patient as part of its US clinical trial.

The company previously indicated it would reach the milestone before the end of 2005.

TGA acts on melatonin imports with infringement notices totalling $99K

Laboratory testing of several imported unregistered melatonin products has confirmed them to be...

Scientists search for cystitis pain 'off switch'

By targeting certain pain receptors in the bladder, Australian scientists believe that the...

Australia's first cases of H5 avian influenza confirmed

Positive results for H5 avian influenza (bird flu) have been confirmed in two seabirds found in...

Content from other channels on our network

Blueberry packing house automates sorting after expansion

Suntory Oceania releases 2025 Sustainability Report

AIP to partner with the Packaging Cockpit

WHS guidelines released on risks of AI in the workplace

Lactalis plans to close dairy factory in Gippsland, ADF comments

CEFC announces new CEO

$32 million investment to create jet fuel from forest waste

Australia's data centre future will be built on concrete — so make it more sustainable

WA wind farm to generate power for 100,000 homes

Ampd launches next-gen battery storage for heavy industries

ASD issues guidance for OT network isolation

Inaugural scholarships to support future heavy industry decarbonisation

Magnetic invention removes microplastics and some PFAS from wastewater

ARENA backs aviation fuel from forestry byproducts

Transgrid to deploy synchronous condensers for NSW grid